KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of TRKA independently of its demethylase activity in chronic myelogenous leukemia

Rationale: Despite landmark therapy of chronic myelogenous leukemia (CML) with tyrosine kinase inhibitors (TKIs), drug resistance remains problematic. Cancer pathogenesis involves epigenetic dysregulation and in particular, histone lysine demethylases (KDMs) have been implicated in TKI resistance. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chengwan, Shen, Li, Zhu, Yifu, Xu, Ran, Deng, Zhikui, Liu, Xiaoning, Ding, Yihan, Wang, Chunling, Shi, Yuye, Bei, Liye, Wei, Dongping, Thorne, Rick F., Zhang, Xu Dong, Yu, Liang, Chen, Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806474/
https://www.ncbi.nlm.nih.gov/pubmed/33456567
http://dx.doi.org/10.7150/thno.50571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806474/
https://www.ncbi.nlm.nih.gov/pubmed/33456567
http://dx.doi.org/10.7150/thno.50571

Ejemplares similares